V ascular endothelial growth factor (VEGF) is an endothelial cell-specific growth factor, secreted as a 34-42 kDa, heparin-binding, homodimeric glycoprotein. There are five human isoforms derived from alternative splicing (VEGF121, 145, 165, 189, 206), 1 of which VEGF121 and VEGF165 are soluble ones. VEGF is commonly expressed in a wide variety of human and animal tumor cells. The expression of VEGF has been suggested to be related to fundamental features of tumors, such as growth rate, microvessel density, vascular architecture and the development of tumor metastasis. [2] [3] [4] [5] Clinical studies have demonstrated that the levels of VEGF mRNA and protein expression often correlate positively with malignant progression. [6] [7] [8] The importance of VEGF-induced angiogenesis in solid tumors is well established, while its significance in hematologic malignancies remains unclear. VEGF was originally cloned from a human leukemic cell line HL60. 9 Furthermore, the expression of VEGF was found in many hematopoietic cell lines, 10 and a positive role of VEGF in regulating normal hematopoiesis has been suggested by several groups. 11, 12 Only recently, angiogenesis has been speculated to be critical for proliferation of leukemic cells based on a significantly increased level of VEGF in a variety of hematologic malignancies. 13 In addition, the cellular level of VEGF has been suggested as an independent predictor of outcome in acute myeloid leukemia (AML) patients with high white blood cell and blast counts, 14 and correlated with prognosis in patients with chronic lymphocytic leukemia (CLL). 15 In patients with chronic myeloid leukemia (CML), increase in the number of blood vessels has been associated with a significant increase in only VEGF, but not bFGF. 16 VEGF receptors were also found to express at a moderate-to-strong level in some leukemic cell lines. 13 Reactivation of VEGF receptors may thus be one mechanism by which certain subsets of leukemic cells establish their autonomous growth. It has been suggested that in hematologic malignancies, VEGF facilitates tumor proliferation and tissue angiogenesis through both leukemic and endothelial cells. Therefore, interference of VEGF-induced angiogenesis and leukemic cell growth could have an anticancer effect. Here, we report that downregulation of the VEGF in K562 leukemic cells using antisense strategy can result in both antiangiogenic and antitumor growth in vitro and in vivo.
Materials and methods

Cell line
K562, a human erythroleukemia cell line, was grown in RPMI-1640 with 10% fetal bovine serum (FBS) and penicillin/streptomycin mix (100 U/ml and 100 mg/ml, respectively). Human umbillical vein endothelial cells (HUVECs) were prepared from human umbilical cord as described previously. 17 HUVECs were grown on fibronectin-coated culture dishes in medium 199 with 20% FBS, and penicillin/streptomycin mix (100 U/ml and 100 mg/ml, respectively), and were used for experiment between passages 1 and 2.
Construction of pIRES2-antisense-VEGF121 vector VEGF121 cDNA was amplified by reverse transcription-PCR (RT-PCR) using the following primers 5 0 GGG CTC GAG TCA CCG CCT CGG CTT GTA AC 3 0 (sense) and 5 0 GGG GGA TCC ATG AAC TTT CTG CTG TCT TG 3 0 (antisense). Subsequently, the 444-bp VEGF121 cDNA was inserted in an antisense orientation into the XhoI and the BamHI site of pIRES2-EGFP (Clontech) to antisense-VEGF plasmid construct. The orientation of antisense-VEGF plasmid was determined by means of restriction enzyme analysis and DNA sequencing.
DNA transfection and selection of clones
K562 cells were either transfected with the antisense-VEGF or pIRES2 vector control using lipofectamine 2000 (LF2000) according to the manufacturer's protocol (Life Technologies, Gaithersburg, MD). Briefly, 6 Â 10 5 K562 cells were seeded into an individual well of a 24-well plate. For cells of each well to be transfected, 1 mg of DNA and 2 ml LF2000 were diluted into 50 ml OPTI-MEM I medium (Life Technologies), respectively. Once the LF2000 was diluted, it was incubated with the DNA at room temperature for 30 minutes to allow DNA-LF2000 complex to form, and then the complex was directly added to each well containing cells. Drug selection was started after 48 hours post-transfection by adding 500 mg/ml G418 in RPMI-1640 with 10% FBS to the culture. After 1 week, the cells were removed from the cultures and 2000 cells were replated in methylcellulose medium (1% methylcellulose in RPMI-1640 with 10% FBS and 500 mg/ml G418). After 10 days, G418-resistant colonies were transferred separately to an individual well of a 96-well plate. Colonies were expanded.
RT-PCR analysis
Total RNA was extracted using mini DNA-free total RNA extraction kit (Waston Shanghai) following the manufacture's instructions. Complementary DNA (cDNA) was subsequently synthesized from total RNA using SUPERSCRIPT I RNaseH Reverse Transcriptase (Life Technologies). Different aliquots of cDNA were amplified with specific primers for antisense-VEGF insert, VEGF and VEGFR-1. The b-actin was used as a control for successful cDNA synthesis and semiquantitation analysis. For antisense-VEGF insert, PCR was performed under standard condition with 35 cycles of 30 seconds at 941C, 1 minute at 601C and 1 minute at 721C, using a sense primer that corresponds to the region of the CMV sequence of the pIRES2 cloning vector and an antisense primer that corresponds to the 5 0 terminal sequence of the VEGF cDNA inserts. For VEGF and VEGFR-1, PCR were performed using the appropriate primers and reaction conditions as described previously. 18 Conditioned medium (CM) and VEGF ELISA The ELISA kit specific for human VEGF was purchased from R&D systems (Minneapolis, MN) and used to measure the levels of VEGF produced by the cells. To prepare the CM, 1.5 Â 10 6 antisense-VEGF K562 cells and vector control K562 cells were cultured in serum-free RPMI-1640, and the culture supernatants were collected after 72 hours and used without further dilution. The experiments were done in duplicate and repeated three times.
Endothelial cell proliferation assays
HUVECs were grown on fibronectin-coated culture dishes until 80-90% confluence. Cells were subcultured at a ratio of 1:2, and the HUVECs from the second passage were used in the proliferation assay. HUVECs (5 Â 10 3 ) per well were plated in 96-well plates in M199 containing 8% FBS with 50% concentration (v/v) CM. At 48 h, the MTT assays were performed. Briefly, 20 ml of a 5 mg/ml solution of MTT was added to the wells and incubated at 371C for 4 hours. The supernatant was removed, and the reaction was stopped with dimethlsulfoxide (100 ml/well). The plates were placed on a shaker for 1 minute, and the absorbance was determined on a plate reader at 490 nm.
Migration assay
Migration assays were performed in transwell chamber (8-mm pore size) (Corning-Costar Corp.,Cambridge, MA). A volume of 500 ml CM from antisense-VEGF K562 cells or vector control K562 cells was placed in the lower chambers. HUVECs were trypsinized and resuspended in serum-free RPMI-1640, and then 100 ml of 1 Â 10 6 per ml HUVECs were placed in the upper chambers. After 4 hours of incubation at 371C, cells on the lower chambers were collected, spun down at 1000 rpm, and counted by FACS at least three times.
In vitro tumor cell growth rate
Antisense-VEGF K562 cells and vector control K562 cells were seeded into 96-well plates at a concentration of 10 4 cells per well and grown in serum-free RPMI-1640. At different time points (every 24 hour), the MTT assays were done as described above. Cell proliferation assays were also done in six-well plates in serum-free RPMI-1640. After 24, 48, and 72 hours, viable cells (as determined by trypan blue exclusion) were counted using a hemocytometer.
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Quantification of apoptotic cells in serum-free conditions
To determine survival in serum-free conditions, antisense-VEGF K562 cells and vector control K562 cells were cultured in six-well plates at a cell density of 2 Â 10 5 cells per well, in serum-free RPMI-1640 for 72 hours. The cells were collected, spun down at 1000 rpm, and then analyzed by FACS for the presence of apoptotic cells using the annexin V-PE kit (Bender Medsystems) following the manufacturer's instructions.
Protein extraction and Western blotting
Total protein extracts from cells were obtained by lysing antisense-VEGF K562 cells or vector control K562 cells in cold lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40 and 0.5% deoxycholic acid), in the presence of protease inhibitors (10 mg/ml leupeptin, 1 mM PMSF). Proteins from cell supernatants were concentrated using 10,000 molecular weight concentration column (Millipore, Bedford, MA). Proteins were quantified by Bio-Rad protein assay (Bio-Rad laboratories, Hercules, CA). Supernatants (a total protein of 250 mg) were suspended in loading buffer and subjected to SDS-PAGE (12% gels) in the presence of b-mercaptoethanol. Proteins were subsequently blotted onto PVDF membranes following conventional protocols. Finally, blots were blocked in 5% bovine serum albumin (BSA)/ PBS-1% Tween 20 at 41C overnight. Rabbit polyclonal anti-VEGF and anti-Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were used at 1:200 dilutions and secondary anti-rabbit IgG-HRP were used at 1:5000. The DAB detection system was used to visualize the presence of proteins on the PVDF blots.
Animal studies
Female nu/nu nude mice (6-8 weeks old) of BABL/c background were obtained under strict pathogen-free conditions, receiving sterilized pellets and water ad libitum. Antisense-VEGF K562 cells or vector control K562 cells (1.5 Â 10 7 in 200 ml of serum-free RPMI-1640) were injected subcutaneously into the right flank of the mice. Tumors were measured twice weekly with calipers, and tumor volumes were calculated by the formula [p/6 (w1 Â w2 Â w2)], where w1 represents the largest tumor diameter and w2 represents the smallest tumor diameter. Mean tumor volumes were calculated from measurements performed on five mice in each of three individual experiments. After 2 or 3 weeks after implantation, the mice were killed and the sites of tumor implantation were isolated. Metastases at distant sites were not found. Mice with no sign of tumor growth were kept observation for 2 months. To determine if the antisense-VEGF sequence remained intact for transcription, Genomic DNA was extracted from about 25 mg-tumor tissue through genome DNA extraction kit (Waston, Shanghai), PCR amplifications of the insert were performed on DNA samples of K562 tumors obtained 14 days after the initial injection of cells. Two PCR primers and the reaction condition, which were designed to confirm the presence of the insert, were used as described above.
Histology
Tumors were removed from mice and immediately frozen in liquid nitrogen until use. Frozen sections were cut serially through the entire tumor for examination of vessel density and tumor apoptosis. Tumor microvessels were stained using a mouse monoclonal antibody to the CD31 antigen (PharMingen) on endothelial cells. Sections were fixed in acetone (10 
. Calculations were performed on five fields selected at random/section. TUNEL staining was performed on paraffin-embedded sections of tumor using an in situ cell death detection kit according to the manufacturer's instructions (Roche Molecular Biochemicals, Germany).
Statistical analysis
Student's t-test was used to compare the mean differences between samples using the statistical software SPSS version 11.5.
Results
K562 cells expressing antisense-VEGF121
The 444-bp VEGF121 insert amplified by RT-PCR was cloned into the XhoI and the BamHI site of the eucaryotic expression vector, pIRES-2-EGFP. The orientation of antisense-VEGF constructs was confirmed by means of restriction enzyme mapping and DNA sequencing. Following transfection of K562 cells with the antisense-VEGF construct (or vector alone as a control) and subsequent antibiotic selection, individual clones were isolated and grown in 96-well culture plates and expanded. These clones were positive for GFP expression under fluoromicroscope and the expression of antisense-VEGF cDNA insert was confirmed by RT-PCR (Fig 1a) .
Downregulation of endogenous VEGF expression by antisense-VEGF
RT-PCR analysis was performed on total RNA from either antisense-VEGF K562 cells or vector control K562 cells to assess the levels of VEGF and VEGFR-1 mRNA expression. The results showed that the levels of two variant VEGF mRNA (VEGF121 and VEGF165) exInhibition of K562 leukemia angiogenesis R He et al pressed in antisense-VEGF K562 cells decreased about 83 and 66%, respectively, compared to vector control K562 cells (Fig 1b) , indicating that antisense-VEGF downregulated the expression of endogenous VEGF, likely due to their antisense RNA-targeted degradation. However, the transfer of antisense-VEGF to K562 cells did not affect the expression of VEGFR-1 (Fig 1c) .
ELISA analysis and Western blotting were performed to determine the amount of secreted VEGF protein in culture media. K562 cells were grown in serum-free medium for 3 days, and the secreted proteins of VEGF in culture media were determined by ELISA and Western blotting. Compared to vector control K562 cells, antisense-VEGF K562 cells showed a 2.4-fold decrease of the secreted VEGF level (Po.01) by ELISA (Fig 2a) . Correspondingly, Western blotting analysis of concentrated culture supernatants showed that the level of VEGF secretion in antisense-VEGF K562 cells was significantly decreased when compared to vector control K562 cells (Fig 2b) .
Effects of CM from antisense-VEGF K562 cells on HUVECs
To evaluate the effects of decreased level of VEGF on the proliferation and migration of endothelial cells, CM of K562 cells were assayed for their potential on HUVECs. The proliferation of HUVECs induced by the CM from antisense-VEGF K562 cells was decreased 1.75-fold by day 2, compared with CM from vector control K562 cells (Po.01) (Fig 3a) . Endothelial cell migration assays were performed in transwell chambers as described in methods. As showed in Fig 3b, the CM from antisense-VEGF K562 cells caused a 1.9-fold decrease of HUVEC migration, compared with the CM from vector control K562 cells (Po.01). No difference was found in the proliferation and 
In vitro growth properties of antisense-VEGF K562 cell line
It has been shown that leukemia cells expressed VEGF and its receptors, which resulted in an autocrine loop that mediated leukemia survival. 19 To assess the effect of decreased VEGF on K562 cell survival, cell viability and apoptosis assays were performed in serum-free condition. The expression of antisense-VEGF in K562 cells inhibited growth of K562 cells (Fig 4a and b) and decreased resistance to apoptosis in vitro (Fig 4c) . When cultured in serum-free medium for 72 hours, antisense-VEGF K562 cells underwent a 1.4-fold increase in apoptosis (Po.05) (measured by annexin V + cells), compared to vector control K562 cells. However, Western blot analyses of cell lysates did not show any difference in Bcl-2 protein levels in both antisense-VEGF K562 cells and vector control K562 cells (data not shown).
Xenograft tumor growth
The injection of nude mice with either antisense-VEGF K562 cells or vector control K562 cells was performed to determine the effectiveness of downregulation of VEGF on tumor growth in vivo. Lower tumor incidence was found in mice injected with antisense-VEGF K562 cells (about 70%, n ¼ 5), compared to mice with vector control K562 cells (100%, n ¼ 5). Moreover, subcutaneous injection of nude mice with antisense-VEGF K562 cells decreased the growth rate of leukemic cells in vivo, compared to vector control K562 cells throughout the experimental time period. Tumor growth was detectable and measurable for vector control K562 cells by day 5 after injection, while the antisense-VEGF cells did not give rise to tumor until day 8. After 14 and 21 days postinjection, the vector control K562 cells generated tumors with mean sizes of 977.547206.80 (SE) mm 3 and 1404.587204.03 (SE) mm 3 , respectively, while the tumors grown from the antisense-VEGF K562 cells had mean sizes of 275.08792.06 (SE) mm 3 and 440.387146.77 (SE) mm 3 (Po.005) (Fig 5) . Sections of tumor using TUNEL staining were analyzed for the degree of tumor cell apoptosis in vivo. An increase of cell apoptosis was noted in the tumors from antisense-VEGF K562 cell, compared to those from vector control K562 cells (Fig 6a and b) . Furthermore, PCR analysis demonstrated that the antisense-VEGF sequence was detectable in the cells located in the tumors derived from the antisense-VEGF K562 cells, but not from the vector control K562 cells.
Microvessel count in tumors
To determine whether the reduction of VEGF expression was associated with a decreased potential to induce neovascularization, microvessel density was examined in tumor tissues by immunostaining with anti-CD31 monoclonal antibody. The average of blood vessels observed in the tumors derived from the antisense-VEGF cells were markedly lower (1070.35 (SE)/field) than in control tumor (20.771.75 (SE)/field) (Po.01) (Fig 6c and d) , indicating an inhibition of tumor angiogenesis after decreasing the level of VEGF in leukemia cells by antisense-VEGF.
Discussion
There are increasing evidences indicating that VEGF plays a role in cancer development and progression not Inhibition of K562 leukemia angiogenesis R He et al only in solid tumor but also in hematologic malignancies including acute and chronic leukemia, myelodysplasia, non-Hodgkin's lymphoma and multiple myeloma. 20 In addition, Gerber et al. 21 have observed that VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Considering leukemia as clonal derivatives of hematopoietic progenitor cells, one can speculate that disrupting the internal autocrine loop by downregulation or even ablation of the endogenous VEGF production might have therapeutic effect on hematologic malignancies. Recognition of the important role of VEGF resulting from autocrine and/or paracrine regulation in hematologic malignancies has raised expectations for VEGF as an emerging target for antileukemia intervention. The corresponding strategies include decreasing the production of VEGF (antisense strategy), 22 blocking the binding of VEGF to its receptors (monoclonal anti-VEGF or soluble receptor), 23, 24 and inhibiting VEGF receptor tyrosine kinases. 25, 26 Several investigators have suggested the use of vectormediated gene therapy of antisense sequence in tumor models. 27, 28 In the present studies, we assessed the feasibility of disrupting the VEGF/VEGF receptor signal pathway by antisense-VEGF expression in leukemia. We used K562 cell line for this study for several reasons. This cell line expresses high levels of VEGF mRNA, secretes the VEGF protein and expresses the VEGF receptors. 29 This cell line has higher transfection efficiency by LF2000 than other suspension leukemia cell lines. Finally, the K562 cells are able to form tumor in mice in vivo. We first investigated the antitumor and antiangiogenesis effects of antisense-VEGF in K562 cells in vitro. To minimize interference of other growth factors in the serum, the experiments were carried out under serum-free orreduced conditions. The expression of antisense-VEGF in K562 cells efficiently decreased VEGF mRNA and the secretion of VEGF in the supernatants of cells. Furthermore, the decreased VEGF in K562 cells by antisense-VEGF resulted in an inhibition of growth and migration of endothelial cells in a paracrine fashion.
Previous studies have showed that elevated circulating VEGF level will confer VEGFR + expressing tumor cells with great survival potential and resistance to apoptosis in an autocrine fashion by inducing Bcl-2 expression on VEGFR + primary leukemia and cell lines. 30 According to other's and our data, VEGFR-2 is not expressed or very weakly in K562 cells, whereas VEGFR-1 is highly expressed in K562 cells. 13, 19 It is known that VEGF/ VEGFR-2 autocrine loop is more important for mediating the proliferation and survival of leukemia cells than VEGF/VEGFR-1 which is primarily involved in the migration of leukemia cells. 19, 26 Interestingly, we observed that the expression of antisense-VEGF resulted in the decrease of K562 cell proliferation and the increase of apoptotic cells, as compared with control vector-transfected cells under serum-free condition. However, no detectable change of the Bcl-2 level in antisense-VEGF transfected cells was found as determined by Western blotting, compared with control vector-transfected cells. Furthermore, the expression of antisense-VEGF in K562 cells had no detectable effect on VEGFR-1 expression by RT-PCR analysis. Correspondingly, there was no significant difference in cell migration induced by VEGF between antisense-VEGF K562 cells and vector control K562 cells in vitro. The precise mechanism to explain these phenomena remains unknown. Autocrine VEGF may promote an invasive phenotype of leukemia cells, a mechanism through which extramedullary leukemia masses are established. 20 Therefore, further investigation will be required to determine whether the downregulation of VEGF secretion from leukemia cells by antisense strategy could affect metastatic behavior in vivo. Inhibition of K562 leukemia angiogenesis R He et al Subsequent in vivo experiments found that the reduction of VEGF expression in K562 cells not only severely suppressed the growth of these tumors but also obviously inhibited tumor angiogenesis and promoted leukemia cell apoptosis. These observations suggest that VEGF is the principle mediator of leukemia angiogenesis and that the absence of VEGF response cannot be adequately compensated by other angiogenic factors.
In summary, we have demonstrated that downregulation of VEGF expression in K562 cells using antisense strategy significantly inhibits tumor angiogenesis and tumor growth. Our finding furthermore underlines the role of VEGF signaling pathway in leukemia pathogenesis. Thus, the antisense-VEGF strategy may offer an exciting avenue of gene therapy development as an adjuvant treatment for human hematological malignancies.
